Biodexa Pharmaceuticals (BDRX) Amortization - Intangibles (2014 - 2020)
Biodexa Pharmaceuticals (BDRX) posted Amortization - Intangibles of -$16.3 million for Q4 2020, down 11.9% sequentially from -$14.6 million in Q3 2020.
Biodexa Pharmaceuticals (BDRX) Amortization - Intangibles (2014 - 2020) Analysis & Trends
Biodexa Pharmaceuticals has reported Amortization - Intangibles for 3 years, with the latest figure at -$16.3 million in Q4 2020.
- Quarterly Amortization - Intangibles changed N/A year-over-year to -$16.3 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was -$51.1 million (changed N/A YoY) and the FY2020 annual result came in at -$15.9 million, changed N/A from the prior year.
- Amortization - Intangibles declined to -$16.3 million in Q4 2020 per BDRX's latest filing, from -$14.6 million in the prior quarter.
- Over five years, Amortization - Intangibles peaked at -$14.6 million in Q3 2020 and troughed at -$16.3 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -16.33 Mn |
| Sep 10, 2020 | -14.60 Mn |
| Dec 31, 2015 | -17.32 Mn |
| Dec 31, 2014 | -2.85 Mn |